LYEL stock forecast, quote, news & analysis
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... Show more
Why Lyell Immunopharma (LYEL) Stock Is Up +12% in the Last 30 Days
Key Takeaways
- Lyell Immunopharma (LYEL) shares have rallied approximately 12% over the past 30 days, rebounding from a multi-month low of $11.61 reached in late June 2026.
- The stock remains under significant pressure on a quarterly basis, having declined roughly 40% from late April levels amid a broader biotechnology sector downturn.
- A fresh analyst initiation from Stifel with a Buy rating and a $44 price target provided a notable sentiment boost in late July.
- Clinical momentum continues to build, with the PiNACLE pivotal trial for lead candidate ronde-cel progressing toward a data readout in the second half of 2026 and a BLA filing expected in 2027.
- The company held approximately $261 million in cash as of March 31, 2026, providing an anticipated runway into the third quarter of 2027.
- Investors are closely watching upcoming clinical data updates for both ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer.
Lyell Immunopharma (LYEL) Company Overview and Market Position
Lyell Immunopharma is a late-stage clinical biotechnology company focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. Headquartered in South San Francisco, California, the company leverages a proprietary suite of technologies designed to enhance CAR T-cell durability, stemness, and functionality within the hostile tumor microenvironment. Its lead candidate, ronde-cel (rondecabtagene autoleucel), is a dual-targeting CD19/CD20 CAR T-cell therapy currently in two pivotal trials for relapsed/refractory large B-cell lymphoma (LBCL). The FDA has granted ronde-cel Regenerative Medicine Advanced Therapy (RMAT) designation in both the third-line-plus and second-line settings, as well as Fast Track designation. Lyell's second major candidate, LYL273, targets guanylyl cyclase C (GCC)-expressing cancers, with an initial focus on metastatic colorectal cancer. The company operates its own LyFE Manufacturing Center, which is designed for commercial-scale production. Lyell competes in the rapidly evolving CAR T-cell space alongside established players such as GILD (Kite), NVS (Novartis), and BMY (Bristol Myers Squibb).
Lyell Immunopharma (LYEL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, LYEL shares have gained approximately 12%, moving from a closing price of $11.61 on June 26, 2026, to $13.00 as of July 28, 2026. The stock touched a 2026 low near $11.47 during intraday trading in late June before staging a recovery. This rebound reflects a partial unwinding of deeply oversold conditions that built up during the preceding months.
The quarterly picture tells a starkly different story. From a closing price of $21.49 on April 28, 2026, LYEL has fallen roughly 40% through late July, erasing the majority of gains accumulated during the first quarter of the year. The stock traded as high as $25.25 intraday in mid-April before entering a prolonged downward trend that persisted through most of May and June. The quarterly decline was driven by a combination of broader risk-off sentiment in the biotechnology sector, a lack of near-term catalysts during the late spring months, and ongoing cash-burn concerns common to pre-revenue clinical-stage companies.
What Drove LYEL Stock Price in the Last 30 Days
The 12% recovery in LYEL over the past 30 days can be attributed to several converging factors. First, the stock reached technically oversold levels in late June, with the closing price of $11.61 on June 26 representing a decline of more than 50% from the mid-April highs. Deeply discounted valuations attracted bargain-seeking investors and traders anticipating a mean reversion.
Second, Stifel initiated analyst coverage of Lyell Immunopharma on July 22 with a Buy rating and a $44 price target, representing substantial upside from the stock's trading levels at the time. The initiation highlighted the registrational-stage positioning of ronde-cel and the potential of LYL273 in solid tumors, reinforcing the investment thesis for the company's pipeline.
Third, Lyell's participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30 kept the company visible among institutional and retail investors focused on the cell therapy space. Additionally, the company presented Phase 1/2 safety and translational data for ronde-cel at the European Hematology Association (EHA) 2026 Congress in June, which included a 97% manufacturing success rate among 108 treated patients, underscoring the reliability of its LyFE Manufacturing Center.
Lastly, broader market dynamics played a role. A modest stabilization in the biotechnology sector during July helped lift heavily shorted and oversold names, with LYEL benefiting from the improving risk appetite in the healthcare space.
What Drove LYEL Stock Performance Over the Last Quarter
The roughly 40% decline in LYEL over the past quarter was shaped primarily by the biotechnology sector's broader downturn rather than company-specific setbacks. After a strong start to 2026 that saw LYEL climb above $25 in mid-April — buoyed by the closing of the second $50 million tranche of its equity private placement and the commencement of patient dosing in the PiNACLE-H2H Phase 3 trial — selling pressure intensified in late April and persisted through June.
Several macro and sector-level forces contributed. Rising interest rate expectations and a rotation out of high-risk, pre-revenue biotechnology names weighed heavily on the stock. Lyell's Q1 2026 earnings report on May 6, while showing a narrowed net loss of $24.2 million compared to $52.2 million in the prior-year period, did not contain major new clinical data that could counteract the negative sentiment from broader market headwinds. The company's revenue remained minimal at just $2,000 for the quarter, consistent with its pre-commercial stage.
Investor concerns about dilution risk also lingered despite the completed $100 million private placement. The private placement shares were sold at $25.61 per share, well above current trading levels, which highlighted the valuation gap but also raised questions about future financing needs as Lyell advances its costly pivotal trials.
Trending AI Robots
For investors seeking data-driven trading strategies across thousands of equities, Tickeron's Trending AI Robots page offers a curated selection of top-performing artificial intelligence trading bots. Tickeron hosts hundreds of AI-powered trading bots that execute across a wide range of tickers, strategies, and timeframes — from short-term swing trading to longer-term trend-following approaches. The Trending AI Robots section highlights only those bots that have demonstrated standout performance and relevance in current market conditions, helping traders identify actionable algorithmic insights at a glance. Bots vary by risk profile, holding period, and performance metrics, allowing users to explore models aligned with their individual trading styles. Visit the Trending AI Robots page to see which strategies are capturing opportunities in today's markets.
LYEL Stock Forecast Drivers: What Investors Should Watch Next
The investment narrative for LYEL in the months ahead will be heavily shaped by clinical catalysts. Additional data from the PiNACLE pivotal trial evaluating ronde-cel in third-line-plus LBCL is expected in the second half of 2026, with pivotal data anticipated in mid-2027. Any updates on overall response rates and duration of response will be closely scrutinized. Simultaneously, enrollment progress in the PiNACLE-H2H head-to-head Phase 3 trial comparing ronde-cel against standard-of-care CD19 CAR T-cell therapies will serve as an important operational milestone.
For LYL273, safety data from the ongoing Phase 1 dose-escalation trial in metastatic colorectal cancer is expected in the first half of 2026, with a second update including clinical outcomes anticipated later in the year. Positive data could significantly expand Lyell's addressable market beyond hematologic malignancies. The company also plans an FDA discussion by year-end 2026 to support a potential pivotal colorectal cancer trial in the first half of 2027.
On the financial side, investors will monitor cash burn rates and the company's balance sheet. With approximately $261 million in cash as of March 31, 2026, Lyell has guided that its runway extends into the third quarter of 2027 — but any acceleration in spending or delays in clinical timelines could alter that trajectory. Macroeconomic conditions, particularly interest rate policy and sector-level flows into biotechnology, will continue to influence LYEL's valuation alongside company-specific developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LYEL sees its Stochastic Oscillator climbs out of oversold territory
On July 30, 2026, the Stochastic Oscillator for LYEL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LYEL just turned positive on July 30, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LYEL as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
LYEL broke above its upper Bollinger Band on July 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LYEL entered a downward trend on July 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LYEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.159) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology